J vasc surg_review_2013

AAA

REVIEW ARTICLES
Richard P. Cambria, MD, Section Editor
From the Canadian Society for Vascular Surgery
Mortality and reintervention following elective
abdominal aortic aneurysm repair
Mohammad Qadura, MD, PhD,a
Farhan Pervaiz, BSc,a
John A. Harlock, MD, FRCSC,a
Ashraf Al-Azzoni, MD,b
Forough Farrokhyar, PhD,c,d
Kamyar Kahnamoui, MD, MHRM,c,d
David A. Szalay, MD, MEd, FRCSC,a
and Theodore Rapanos, MD, MSc, FRCSC,a
Hamilton, Ontario, Canada
Background: The objective of this study is to provide an up-to-date meta-analysis on the short- and long-term mortality
rates of elective repair of abdominal aortic aneurysms (AAAs) via the open and endovascular approaches.
Methods: MEDLINE, EMBASE, and Cochrane Central Register of Controlled trials, conference proceeding from major
vascular meetings were searched for randomized trials comparing open vs elective endovascular aneurysm repair (EVAR)
of AAAs. A random-effects model was used for analysis. Risk ratio (RR) and 95% confidence intervals (CIs) of open vs
EVAR were calculated for short- and long-term mortality and reintervention rates.
Results: The analysis encompassed four randomized controlled trials with a total of 2783 patients. The open repair group
resulted in significantly increased 30-day postoperative all-cause mortality compared with EVAR repair group (3.2% vs
1.2%; RR, 2.81; 95% CI, 1.60-4.94); however, there is no statistical difference in the long-term all-cause mortality
between both groups (RR, 0.97; 95% CI, 0.86-1.10). Interestingly, fewer patients underwent reintervention procedures
in the open repair group compared with those who had EVAR repair (9.3% vs 18.9%; RR, 0.49; 95% CI, 0.40-0.60), but
this finding is doubtful due to the large heterogeneity. Lastly, no statistical difference in long-term mortality rates
attributable to cardiovascular disease (CVD), aneurysm related, or stroke were found between the two types of repair.
Conclusions: Results of this meta-analysis demonstrate that the 30-day all-cause mortality rate is higher with open than
with EVAR repair; however, there is no statistical difference in the long-term all-cause and cause-specific mortality
between both groups. The reintervention rate attributable to procedural complication was higher in the EVAR group.
Because of the equivalency of long-term outcomes and the short-term benefits of EVAR, an endovascular-first approach
to AAAs can be supported by the meta-analysis. (J Vasc Surg 2013;57:1676-83.)
As a frequent cause of cardiovascular mortality, abdom-
inal aortic aneurysms (AAAs) place a significant burden on
health care systems in developed nations.1,2
Recent studies
have shown a prevalence of AAA as high as 9% in people
65-85 years of age.2
The risk of rupture, which is fatal in
65% of individuals, is directly correlated with the aneu-
rysm’s diameter.3
Surgical intervention is currently the
accepted standard used to prevent mortality from aneurysm
rupture. This can be approached from either a standard
open technique or an endovascular procedure with a stent
graft system. The open approach, practiced by surgeons for
over 50 years, had been the treatment of choice until a less
invasive alternative, endovascular aneurysm repair (EVAR),
was developed.4
With similar indications for both
approaches, deciding on an elective repair method can be
very challenging. Several trials have compared the EVAR
and open approaches, focusing on their effectiveness and
outcomes. However, there are still some controversies in
the literature on the short- and long-term mortality rates
of these approaches.2
Our goal is to review the current
evidence comparing the open and EVAR approaches for
AAA repair by performing a meta-analysis of all the
randomized controlled trials that compared both
approaches with regard to their effectiveness and safety.
METHODS
Design. A systematic review and meta-analysis of
randomized clinical trials were conducted.
Outcome of interest. The primary outcome of
interest was short- and long-term all-cause mortality. We
considered mortality within 30 days after the operation to
represent the short-term mortality rate, whereas mortality
From the Division of Vascular Surgery,a
Division of Cardiology,b
Division of
General Surgery,c
and Department of Clinical Epidemiology and Bio-
statistics,d
McMaster University.
Author conflict of interest: none.
Presented at the Thirty-fourth Annual Meeting of the Canadian Society for
Vascular Surgery, Quebec City, Quebec, Canada, September 28-29, 2012.
Additional material for this article may be found online at www.jvascsurg.org.
Reprint requests: John A. Harlock, MD, FRCSC, Division of Vascular
Surgery, McMaster University, Hamilton General Hospital, 237 Barton
St E, Hamilton, Ontario, Canada L8L 2X2 (e-mail: harlocj@mcmaster.ca).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a conflict of interest.
0741-5214/$36.00
Copyright Ó 2013 by the Society for Vascular Surgery.
http://dx.doi.org/10.1016/j.jvs.2013.02.013
1676
beyond the 2-year mark was considered to represent the
long-term mortality rate. Secondary outcomes of interest
included cardiovascular-related death, aneurysm-related
death, and reintervention rates.
Criteria for study selection. All randomized
controlled trials comparing the mortality rates of EVAR
vs open AAA repair were included. Study selection
included randomized controlled trials (RCTs) published
until 2012 that (1) enrolled patients for elective repair
of AAAs with a size $5 cm or AAAs of 4.5 cm that are
rapidly enlarging; (2) all patients were good surgical candi-
dates; and (3) the studies reported all-cause mortality
Table I. Description of the included trials (RCTs)
Source
Age, mean 6 SD, years
Number of
patients
Inclusion criteria Key exclusion criteria
Follow- up
durationOpen EVAR Open EVAR
ACE 20111
70 6 7.1 68.9 6 7.7 148 150 (1) CT scan finding:
AAA >50 mm in
men, >45 mm in
women, common
iliac artery aneu-
rysm >30 mm
(2) Upper neck free of
major thrombus or
calcification
(3) $15 mm in length
(4) Angle between
neck and axis of
aneurysm <60
mm
(5) Clinical assessment
graded patients in
categories of 0-2
according to
comorbidity score
of SVS/AAVS
(1) Previous AAA
surgery
(2) Ruptured aneurysm
(3) Mycotic aneurysm
(4) Severe iodine
allergy
(5) Life expectancy
deemed <6 months
(6) Category 3 of
SVS/AAVS
4.8 years
DREAM 201014
69.6 þ 6.8 70.7 þ 6.6 178 173 (1) Elective repair
(2) AAA size >5 cm
(3) Suitable for
operation as per
cardiology/inter-
nist for open and
endograft-
dependent
anatomic criteria
for EVAR
(1) Emergency repair
(2) Inflammatory
aneurysm
(3) Anatomic variation
(4) Connective tissue
disease
(5) History of organ
transplant
(6) Life expectancy less
than 2 years
6.4 years
EVAR 112
2011 74.1 6 6.1 74.1 6 6.1 626 626 (1) Elective repair
(2) AAA >5.5 cm
(3) Surgical candidate
(4) Age >60 years
NA 8 years
OVER15
2009 70.5 6 7.8 69.6 6 7.8 437 444 (1) Elective repair
(2) AAA >5 cm
(3) AAA of 4.5 cm
and a rapidly
enlarging
aneurysm
(4) Surgical candidate
(5) An associated iliac
aneurysm with
a maximum diam-
eter of at least 3
cm
(1) Previous abdominal
aortic surgery
(2) Needed urgent
report. Unwilling
or unable to give
informed consent
or follow the
protocol
2 years
AAVS, American Association for Vascular Surgery; AAA, abdominal aortic aneurysm; ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endo-
prothése; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom Endovascular Aneurysm Repair 1; NA, not available;
OVER, Open Versus Endovascular Repair; RCT, randomized controlled trial; SVS, Society for Vascular Surgery.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 6 Qadura et al 1677
(short-term/long-term), aneurysm-related mortality, car-
diovascular disease (CVD)-related mortality (including
congestive heart failure, myocardial infarction, cardiac
arrest), stroke-related mortality, and surgical reintervention
rates. We excluded RCTs that had (1) patients with
previous abdominal aortic surgery, (2) patients who needed
urgent surgery for ruptured AAAs; (3) patients unwilling or
unable to give informed consent or follow the protocol;
and (4) studies with a mean follow-up of less than 2 years.
Literature search and study selection. Studies were
identified by electronic literature searches in the Cochrane
Central Register of Controlled Trials, MEDLINE, and
EMBASE from 1988 to 2012 using combinations of the
following terms: aortic graft, endovascular, EVAR, open,
abdominal aortic aneurysm, AAA, and repair. We also con-
tacted trials’ authors for further data as needed. Our litera-
ture search also included reviewing the references of recent
articles published on this topic including the issues from
the past 12 months of the Journal of Vascular Surgery. All
available data were utilized including full publications,
abstracts, and online late breaking presentations. We identi-
fied 2245 reports that were reviewed by two independent
reviewers (M.Q., F.P.); a third reviewer (T.R.) settled any
discrepancies. A previous meta-analysis was published on
this topic; however, this meta-analysis does not include the
results from the most recent RCTs.5
We also did an analysis
of a number of prospective RCTs but did not include these
in our meta-analysis as per the inclusion criteria.
Data collection. Two authors (M.Q., F.P.) indepen-
dently identified the trials for inclusion and exclusion
criteria as mentioned above. For all published trials, the
following information was tabulated according to the
randomization group by two authors (M.Q., F.P.): (1)
information about the trial’s clinical characteristics, the
number of participating patients, mean age, and duration
of clinical follow-up (Table I); and (2) aneurysm related
mortality, CVD related mortality (including congestive
heart failure, myocardial infarction, cardiac arrest), stroke
related mortality, surgical reintervention rates, short-term
all-cause mortality (<30 days) and long-term mortality
(>2 years with short-term deaths excluded). If no resolu-
tion of agreement was achieved between the reviewers,
a senior author (T.R.) was consulted to settle the discrep-
ancy. The level of agreement between the two authors
(M.Q., F.P.) varied from 83% to 100%.
Assessment of quality and risk of bias. The risk of
bias was assessed according to the guidelines of The
Cochrane Collaboration tool for assessing risk of bias.6-11
The assessment of risk of bias in the trials was based on
consequence generation; allocation concealment; blinding
of participants, personnel, and outcome assessors; incom-
plete outcome data; selective outcome reporting; and other
sources of bias such as baseline imbalance, early stopping
bias, academic bias, and source of funding bias.6
M.Q. and
F.P. assessed the risk of bias in all trials with a third reviewer
(T.R.) to settle any discrepancies.
Statistical analysis. The reliability between the two
reviewers for literature search, kappa score for the
included/excluded studies, data collection, and quality
assessment was measured using kappa statistics and SPSS
software (IBM, Armonk, NY). For dichotomous
outcomes, risk ratio (RR) of open vs EVAR repair with
confidence intervals (CIs) and P value are reported. Results
were considered statistically significant at P # .05. Because
of the possibility of a small number of studies and between-
study heterogeneity, the pooled RR was calculated with the
Mantel-Haenszel method for random effects.6
A random-
effects model meta-analysis assumes that the true under-
lying effects vary between trials. An intention-to-treat
analysis was performed by using the same end point defi-
nitions as in the primary studies. To assess heterogeneity
across trials, we used the Cochrane c2
test based on the
pooled RR. Heterogeneity was considered statistically
significant at P # .1 because the heterogeneity test is
underpowered when small numbers of studies are included.
Also, the I2
statistic was used to quantify heterogeneity;
a value of <25% is considered small heterogeneity, a value
of 25%-50% is considered as moderate heterogeneity,
whereas a value >50% is considered as a large heteroge-
neity.6
Cochrane c2
statistic with P value and I2
value are
reported. A funnel plot is used to explore publication bias,6
but it is not recommended for less than 10 studies because
asymmetry could appear because of chance.12
Review
Manager, v. 5.0 (Cochrane Collaboration, Copenhagen,
Denmark), was used to generate the forest plots and RRs.
RESULTS
Our search identified 2245 abstracts. After review of
the abstracts, we identified four randomized controlled
trials that met our inclusion criteria (Fig 1). All were pub-
lished within the past 4 years. All of the presented results in
this study summarize the findings from the RCTs. None of
the studies was blinded.
The Cohen’s k scores for the interobserver reliabilities
for the literature search process and quality assessment are
Fig 1. Literature research for selected studies.
JOURNAL OF VASCULAR SURGERY
1678 Qadura et al June 2013
0.88, and 0.9, respectively. The data harvest level of agree-
ment among M.Q. and F.P. varied from 83% to 100%.
The literature review also yielded a study by P. W. M.
Cuypers et al 2001.13
However, we have decided not to
include this study in the calculations that are presented.
This article did not elicit the data necessary for our system-
atic review. The only outcome measure presented was
short-term all-cause mortality. The mortality was not sub-
divided by cause, which makes it difficult to compare
with the other studies included in this meta-analysis. To
determine if the exclusion of this study skews the results,
short-term mortality and all-cause mortality were calcu-
lated including this study. The results showed that the
inclusion or exclusion of this study did not alter the overall
outcome (data not shown).
Our literature review identified four trials that are used
in our analysis. These studies reported outcomes of open
repair vs EVAR repair of AAAs in patients who were candi-
dates for both procedures (n ¼ 2783).1,14-17
Table II
summarizes the characteristics of the four RCTs that evalu-
ated AAA repair. Sample size varied from 298 to 1252 with
a similar number of participants in study groups. The mean
age varied from 69 to 74 years, but it was similar between
the groups for all studies. The mean follow-up time varied
from 2 years (United Kingdom Endovascular Aneu-
rysm Repair 1 [EVAR 1], 2011) to 8 years (Anévrisme
de L’aorte Abdominale: Chirurgie versus Endoprothése
[ACE], 2011), but all reported 30-day mortality as short
term. The loss to follow-up for the ACE, Dutch Random-
ized Endovascular Aneurysm Repair (DREAM), EVAR 1,
and Open Versus Endovascular Repair (OVER) studies
was small: 8, 0, 17, and 2 patients, respectively.
Fig 2 shows a significant increased 30-day postopera-
tive all-cause mortality in open repair compared with
EVAR repair (3.2% vs 1.2%; RR, 2.81; 95% CI, 1.60-
4.94). Findings were consistent across the studies. The
between-study heterogeneity was of small size (I2
¼
23%). We also compared the long-term all-cause mortality
between open and EVAR repair. As shown in Fig 3, there is
no statistically significant difference in the long-term all-
cause mortality between open and EVAR repair. RR was
0.95 (95% CI, 0.84-1.10) with no heterogeneity.
A comparison of reintervention rates in both groups
was conducted and summarized in Fig 4. Although there
was no statistical difference in the long-term all-cause
mortality, it is shown in Fig 4 that reintervention proce-
dures in the open repair group were 50% lower than in
the EVAR repair group (9.3% vs 18.9%; RR, 0.49; 95%
Table II. The assessment of risk of bias in the trials was based on sequence generation; allocation concealment; blinding
of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other
sources of bias such as baseline imbalance, early stopping bias, academic bias, and source of funding bias
Bias DREAM EVAR 1 OVER ACE
Sequence generation Low Moderate Moderate High
Allocation concealment Low Low Low Low
Blinding participants and personnel Moderate-high Moderate-high Moderate-high Moderate-high
Blinding outcome assessment Moderate-high Moderate-high Moderate-high Moderate-high
Incomplete outcome data Low Low Low High
Selective outcome reporting Low Low Low Low
Other sources Moderate Low Low Low
ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United
Kingdom Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair.
Study or Subgroup
ACE1
DREAM16
EVAR 114
OVER17
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.18; Chi² = 3.90, df = 3 (P = .27); I² = 23%
Test for overall effect: Z = 2.45 (P = .01)
M-H, Random, 95% CI
0.50 [0.05-5.49]
3.89 [0.84-18.05]
2.36 [1.18-4.74]
10.16 [1.31-79.03]
2.72 [1.22-6.08]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
Favors Open Favors EVAR
0.01 0.1 1 10 100
Fig 2. Forest plot of randomized trials comparing 30-day mortality rate after endovascular aneurysm repair (EVAR) and
open repair of unruptured abdominal aortic aneurysms (AAAs). Endovascular in comparison to open repair has a lower
30-day postoperative all-cause mortality. ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése;
CI, confidence interval; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom
Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 6 Qadura et al 1679
CI, 0.40-0.60). However, the large between-study hetero-
geneity of 82% undermines the validity of pooled RR for
reintervention.
The long-term mortality was further divided by cause
(cardiovascular, aneurysm related and stroke), and these
were compared in both groups. Fig 5, A-C demonstrate
no statistical difference in long-term mortality rates due
to CVD, aneurysm related and stroke after EVAR or
open repair of AAAs. CVD (RR, 0.9; 95% CI, 0.6-1.2)
and stroke (RR, 0.9; 95% CI, 0.5-1.6) were in favor of
open repair, but aneurysm-related deaths were (RR, 1.1;
95% CI, 0.5-2.5) were in favor of EVAR repair. Heteroge-
neity (I2
¼ 47%) of close to moderate size was present
for aneurysm-related deaths that might be attributable to
the small number of events in ACE 2011 and DREAM
2010 trials.
We have also refined our literature search to include
nonrandomized prospective studies that compared the
short- and long-term mortality events post-EVAR and
open repair of AAAs.18-23
Unlike the results we obtained
from RCT studies, the analysis of the prospective studies
showed no statistical difference in the short-term all-cause
mortality between open repair and EVAR repair
(RR, 1.66; 95% CI, 1.05-2.62). The results from the
long-term all-cause mortality from prospective cohort
studies were not reliable because of the large between-
study heterogeneity (80%). Hatala et al24
recommended
not to pool the results when heterogeneity is larger than
50%. The analysis of the prospective cohort studies showed
no statistical difference in the long-term all-cause mortality
between open repair and EVAR repair (RR, 0.75; 95% CI,
0.53, 1.06).
DISCUSSION
These results represent an up-to-date meta-analysis of
the randomized trials for comparing open vs EVAR repair
of AAAs. Open repair has long been accepted as the gold
standard repair for AAAs because of its acceptable low
risk, predictability for expected outcomes, and durability.
EVAR has been established to help reduce short-term
Study or Subgroup
ACE1
DREAM16
EVAR 114
OVER17
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.91, df = 3 (P = .82); I² = 0%
Test for overall effect: Z = 0.45 (P = .65)
M-H, Random, 95% CI
0.73 [0.35-1.54]
0.93 [0.68-1.28]
0.98 [0.85-1.12]
1.11 [0.67-1.85]
0.97 [0.86-1.10]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
Favors Open Favors EVAR
0.5 0.7 1 1.5 2
Fig 3. Forest plot of randomized trials comparing long-term mortality rate after endovascular aneurysm repair (EVAR)
and open repair of unruptured abdominal aortic aneurysms (AAAs). There was no statistical difference in long-term all-
cause mortality between endovascular and open repair of AAAs. ACE, Anévrisme de L’aorte Abdominale: Chirurgie
versus Endoprothése; CI, confidence interval; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1,
United Kingdom Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair.
Study or Subgroup
ACE1
DREAM16
EVAR 114
OVER17
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.21; Chi² = 16.44, df = 3 (P = .0009); I² = 82%
Test for overall effect: Z = 2.71 (P = .007)
M-H, Random, 95% CI
0.17 [0.06-0.47]
0.61 [0.41-0.91]
0.38 [0.28-0.51]
0.88 [0.59-1.32]
0.49 [0.29-0.82]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
Favors Open Favors EVAR
0.05 0.2 1 5 20
Fig 4. Forest plot of randomized trials comparing reintervention rates after endovascular aneurysm repair (EVAR) or
open repair of unruptured abdominal aortic aneurysms (AAAs). Open in comparison to endovascular repair has a lower
reintervention rate. ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése; CI, confidence interval;
DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom Endovascular Aneurysm
Repair 1; OVER, Open Versus Endovascular Repair.
JOURNAL OF VASCULAR SURGERY
1680 Qadura et al June 2013
mortality associated with elective AAA repair.17
These
initial benefits of EVAR, though, are not sustained on
longer-term follow-up as confirmed with the EVAR 1,
DREAM, and OVER trials as shown in this current
meta-analysis. The French ACE trial found different results
when it came to perioperative outcomes, as no early
survival advantage was attributed to EVAR compared
with open repair. They also found that in low-risk patients,
open repair was as safe as EVAR, but with less
reinterventions.
As demonstrated on most of the trials, the reinterven-
tion rate was higher in the EVAR group of patients. The
DREAM and OVER trials appear to have counted reinter-
vention rates for open and EVAR patients as graft-related
indications, wound-related indications (incisional hernia
and wound infection), and local or systemic indications
(bleeding, endoleak, and small bowel obstructions). The
EVAR 1 and ACE trials appear to have counted reinterven-
tion rates for open and EVAR patients as graft-related
interventions including graft rupture, endoleak, para-
anastomotic aneurysm, graft replacement, and graft occlu-
sions/stenoses. The lifetime need for reintervention in
patients who undergo an EVAR repair approaches 20%.
The OVER trial, though, considered more specifically
surgical complications than both the DREAM and EVAR
1 trials and recorded a 5% rate of patients needing incisional
hernia repairs. As such, OVER did not demonstrate a differ-
ence for reintervention rate between the types of repair. In
Study or Subgroup
ACE1
DREAM16
EVAR 114
OVER17
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 1.54, df = 2 (P = .46); I² = 0%
Test for overall effect: Z = 0.64 (P = .52)
M-H, Random, 95% CI
Not estimable
1.05 [0.51-2.16]
0.93 [0.66-1.32]
0.45 [0.14-1.46]
0.91 [0.67-1.23]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
Favors Open Favors EVAR
Study or Subgroup
ACE1
DREAM16
EVAR 114
OVER17
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.28; Chi² = 5.67, df = 3 (P = .13); I² = 47%
Test for overall effect: Z = 0.26 (P = .80)
M-H, Random, 95% CI
0.17 [0.02-1.38]
2.92 [0.12-71.10]
1.00 [0.69-1.45]
2.20 [0.84-5.74]
1.11 [0.50-2.46]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
Favors Open Favors EVAR
Study or Subgroup
DREAM16
EVAR 114
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.32, df = 1 (P = .57); I² = 0%
Test for overall effect: Z = 0.46 (P = .64)
M-H, Random, 95% CI
1.30 [0.29-5.71]
0.82 [0.44-1.51]
0.88 [0.50-1.54]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
Favors Open Favors EVAR
A
B
C
0.1 0.2 0.5 1 2 5 10
0.01 0.1 1 10 100
0.1 0.2 0.5 1 2 5 10
Fig 5. Forest plot of randomized trials comparing long-term mortality rates due to cardiovascular disease (CVD) (A),
aneurysm related (B), and stroke (C) after endovascular aneurysm repair (EVAR) or open repair of unruptured
abdominal aortic aneurysms (AAAs), respectively. There is no statistical difference in long-term mortality rates because
of CVD, aneurysm related and stroke after EVAR, or open repair of AAAs. ACE, Anévrisme de L’aorte Abdominale:
Chirurgie versus Endoprothése; CI, confidence interval; DREAM, Dutch Randomized Endovascular Aneurysm Repair;
EVAR 1, United Kingdom Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 6 Qadura et al 1681
the ACE trial, there was a statistically significant difference
when it came to wound complications between the open
surgical repair and EVAR arms with 25% of patients under-
going open repair having complications vs 0.7% in the
EVAR group. The ACE trial lists did not specifically record
the incidence of abdominal wall reconstruction or incisional
repairs following open repair group. The incidence of bowel
obstruction associated with open surgery was also not re-
ported. This may have affected the outcomes of their stated
reintervention rate, such as with the OVER trial, as we know
that incisional complications following open repair for
AAA are not negligible.25
The weight of the ACE trial,
though, did not bear out in the Forest plot to affect the
overall swing toward EVAR as requiring a higher rate of
reintervention. This trend is also echoed in the EURO-
STAR registry in which there was an overall 14% reinterven-
tion rate, with complications occurring more frequently in
AAAs >5.5 cm.26
In this current meta-analysis, we found
a higher risk of reintervention for EVAR compared with
open repair. However, the large heterogeneity between
studies undermines the validity of the pooled RR for reinter-
vention. This large heterogeneity might be due to the
definition of and the reasons for reintervention that might
differ from study to study.
In performing this meta-analysis, we were able to look
at the current RCT literature for open vs EVAR repair as
a whole. Any initial benefit that was gained with an
EVAR approach was lost on longer-term follow-up in these
studies. There is no statistical difference in the long-term
mortality comparing open vs EVAR repair. This might be
due to the fact that the length of follow-up varied between
studies from 2 to 8 years.
Further study of long-term mortality by listed cause
demonstrates no difference when comparing either CVD-
related mortality, aneurysm-related mortality, or stroke-
related mortality. This is not overly surprising, as those
who survive the initial periprocedural period often return
back to their baseline risk, independent of type of proce-
dure for AAA repair.
Based on this meta-analysis, we are able to demonstrate
the short-term mortality benefits of an EVAR approach.
For those patients with a life expectancy <2 years, an indi-
vidualized treatment plan is prudent and thoughtful discus-
sion with the patient in regard to overall goals of care
should be had, based on the results of the EVAR 2 trial.27
This group of patients that were deemed unfit to undergo
open AAA repair were not included in our meta-analysis
based on our inclusion criteria.
Although most patients in the DREAM, OVER, and
EVAR 1 were fit for surgery, baseline characteristics may
not be fully identical, and a similar distribution of risk
factors does not fully take into account the association of
risks. The OVER trial used the Research ANd Develop-
ment (RAND) surgical risk score with 53% patients consid-
ered as low risk for surgery. However, the risk assessment
of patients in the EVAR 1 or DREAM was left to each
center’s appreciation. This difference in patient risk assess-
ment may account for the heterogeneity in clinical findings
between the different studies. The ACE trial looked at
patients who were low to moderate risk for undergoing
surgical repair and excluded patients who had a life expec-
tancy of less than 6 months, or were in category 3 of the
Society for Vascular Surgery/American Association for
Vascular Surgery comorbidity score for the clinical assess-
ment. These differences might account for the between-
study heterogeneity for 30-day postoperative mortality.
As with any meta-analysis, the results depend on the
quality and quantity of the studies that were included in
the analysis. Here, the four major randomized controlled
trials for EVAR open repairs have been analyzed, as they
met our search criteria. This includes over 2700 patients
randomized. Other prospective studies were excluded, as
they did not meet our full criteria of randomized trials or
reporting of outcomes beyond 2 years. This does limit our
breadth of studies captured but does help to create a clearer
picture with similar patient groups. Although, as discussed
in our Results section, the inclusion of a number of prospec-
tive nonrandomized trials reaffirms the long-term mortality
equivalency of EVAR and open repairs, but also found
a similar short-term equivalency. These results are inter-
esting and confirm our data for long-term morality. The
difference in the short-term mortality between prospective
studies and RCTs can be attributed to the lack of random-
ization and selection bias of patients. These studies might
have recruited younger patients with few comorbidities
who are better fit to undergo an open repair and the older
patients, or those with more medical comorbidities to
undergo an endovascular repair. Therefore, we must
analyze the prospective studies with caution since they are
prone to selection bias and information bias. Also, because
of the lack of randomization, a higher potential for con-
founding factors can sometimes be observed in prospective
studies.
The strength of this systematic review and meta-
analysis is that any potential biases for search strategy,
inclusion and exclusion of the studies, and data collection
are minimized by an independent review process. Also,
only randomized controlled trials are included, appropriate
statistical methods are used and study heterogeneity is
accounted for in the analysis. The weakness of this study
is the small number of the included studies; we, however,
ensured that all eligible studies were included and our sepa-
rate analysis of nonrandomized prospective trials did not
add much to the conclusions drawn.
CONCLUSIONS
Through this meta-analysis, we are able to confer with
most recent studies on EVAR for AAAs. EVAR reduces the
short-term mortality associated with surgical repair, but
this benefit is not sustained on longer-term follow-up. It
is also confirmed that the reintervention rate was higher
with an EVAR repair. This is an up-to-date review of the
most recent randomized controlled trials comparing open
with EVAR repair for AAAs. This meta-analysis supports
the notion of an endovascular-first approach to AAAs
JOURNAL OF VASCULAR SURGERY
1682 Qadura et al June 2013
attributable to the short-term benefit of EVAR and the
long-term mortality equivalency.
AUTHOR CONTRIBUTIONS
Conception and design: MQ, FP, AA, JH
Analysis and interpretation: MQ, FP, AA, JH, FF, KK, DS
Data collection: MQ, FP
Writing the article: MQ, FP, AA, FF, JH
Critical revision of the article: MQ, JH, FF, KK, DS
Final approval of the article: MQ, DS, JH
Statistical analysis: MQ, FF, KK
Obtained funding: Not applicable
Overall responsibility: JH
REFERENCES
1. Becquemin JP, Pillet JC, Lescalie F, Sapoval M, Goueffic Y,
Lermusiaux P, et al. A randomized controlled trial of endovascular
aneurysm repair versus open surgery for abdominal aortic aneurysm in
low-to-moderate-risk patients. J Vasc Surg 2011;53:1167-73.
2. Sakalihasan N, Limet R, Defaw OD. Abdominal aortic aneurysm.
Lancet 2005;365:1577-89.
3. Kniemeyer HW, Kessler T, Reber PU, Ris HB, Hakki H, Widmer MK.
Treatment of ruptured abdominal aortic aneurysm, a permanent chal-
lenge or a waste of resources? Prediction of outcome using a multi-
organ-dysfunction score. Eur J Vasc Endovasc Surg 2000;19:190-6.
4. Eliason JL, Upchurch GR Jr. Endovascular abdominal aortic aneurysm
repair. Circulation 2008;117:1738-44.
5. Sajid MS, Desai M, Haider Z, Baker DM, Hamilton G. Endovascular
aortic aneurysm repair (EVAR) has significantly lower perioperative
mortality in comparison to open repair: a systematic review. Asian J
Surg 2008;31:119-23.
6. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of
Interventions 2011: Version 5.1.0. The Cochrane Collaboration.
Available at: www.cochrane-handbook.org. Accessed March 2012.
7. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality
and discrepancies between large and small randomized trials in meta-
analyses. Ann Intern Med 2001;135:982-9.
8. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does
quality of reports of randomised trials affect estimates of intervention
efficacy reported in meta-analyses? Lancet 1998;352:609-13.
9. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of
bias. Dimensions of methodological quality associated with estimates of
treatment effects in controlled trials. JAMA 1995;273:408-12.
10. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al.
Empirical evidence of bias in treatment effect estimates in controlled
trials with different interventions and outcomes: meta-epidemiological
study. BMJ 2008;336:601-5.
11. Gluud C, Nikolova D, Klingenberg S, Alexakis N, Als-Nielsen B,
D’Amico G, et al. Cochrane Hepato-Biliary Group. About the Cochrane
Collaboration (Cochrane Review Groups [CRGs]). Chapter 8. Art. No.
LIVER. 2008;4: Available at: http://www.mrw.interscience.wiley.com/
cochrane/cochrane_clsysrev_crglist_fs.html. Accessed November 6, 2009.
12. Duval S, Tweedie R. Trim and fill: a simple funnel-plot based method
of testing and adjusting for publication bias in meta-analysis. Biometrics
2000;56:455-63.
13. Cuypers PW, Gardien M, Buth J, Peels CH, Charbon JA, Hop WC.
Randomized study comparing cardiac response in endovascular and
open abdominal aortic aneurysm repair. Brit J Surg 2001;88:1059-65.
14. EVAR Trial Participants. Endovascular aneurysm repair versus open
repair in patients with abdominal aortic aneurysm (EVAR Trial 1):
randomised controlled trial. Lancet 2005;365:2179-86.
15. Brown LC, Thompson SG, Greenhalgh RM, Powell JT. Incidence of
cardiovascular events and death after open or endovascular repair of
abdominal aortic aneurysm in the randomized EVAR trial 1. Brit J Surg
2011;98:935-42.
16. De Bruin JL, Baas AF, Buth J, Prinssen M, Verhoeven E, Cuypers P,
et al. Long-term outcome of open or endovascular repair of abdominal
aortic aneurysm. N Engl J Med 2010;362:1881-9.
17. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT Jr,
Matsumura JS, Kohler TR, et al; Open Versus Endovascular Repair
(OVER) Veterans Affairs Cooperative Study Group. JAMA 2009;302:
1535-42.
18. Lifeline Registry of EVAR Publications Committee. Lifeline registry of
endovascular aneurysm repair: long-term primary outcome measures.
J Vasc Surg 2005;42:1-10.
19. Cao P, Verzini F, Parlani G, Romano L, De Rango P, Pagliuca V, et al.
Clinical effect of abdominal aortic aneurysm endografting: 7-year
concurrent comparison with open repair. J Vasc Surg 2004;40:841-8.
20. Sicard GA, Zwolak RM, Sidawy AN, White RA, Siami FS. Endovas-
cular abdominal aortic aneurysm repair: long-term outcome measures
in patients at high-risk for open surgery. J Vasc Surg 2006;44:229-36.
21. Moore WS, Matsumura JS, Makaroun MS, Katzen BT, Deaton DH,
Decker M, et al. Five-year interim comparison of the Guidant bifur-
cated endograft with open repair of abdominal aortic aneurysm. J Vasc
Surg 2003;38:46-55.
22. Garcia-Madrid C, Josa M, Riambau V, Mestres CA, Muntana J,
Mulet J. Endovascular versus open surgical repair of abdominal aortic
aneurysm: a comparison of early and intermediate results in patients
suitable for both techniques. Eur J Vasc Endovasc Surg 2004;28:
365-72.
23. Bush RL, Johnson ML, Hedayati N, Henderson WG, Lin PH,
Lumsden AB. Performance of endovascular aortic aneurysm repair in
high-risk patients: results from the Veterans Affairs National Surgical
Quality Improvement Program. J Vasc Surg 2007;45:227-33; discus-
sion: 233-5.
24. Hatala R, Keitz S, Wyer P, Guyatt G. Tips for learners of evidence-
based medicine: 4. Assessing heterogeneity of primary studies in
systematic reviews and whether to combine their results. CMAJ
2005;172:661-5.
25. Raffetto JD, Cheung Y, Fisher JB, Cantelmo NL, Watkins MT,
Lamorte WW, et al. Incision and abdominal wall hernias in patients
with aneurysm or occlusive aortic disease. J Vasc Surg 2003;37:1150-4.
26. Leurs LJ, Buth J, Laheiji RJ; EUROSTAR Collaborators. Long-term
results of endovascular abdominal aortic aneurysm treatment with the
first generation of commercially available stent grafts. Arch Surg
2007;142:33-41.
27. United Kingdom EVAR Trial Investigators. Endovascular repair of
aortic aneurysm in patients physically ineligible for open repair. N Engl
J Med 2010;362:1872-80.
28. Peterson BG, Matsumura JS, Brewster DC, Makaroun MS. Five-year
report of a multicenter controlled clinical trial of open versus endo-
vascular treatment of abdominal aortic aneurysms. J Vasc Surg
2007;45:885-90.
Submitted Oct 25, 2012; accepted Feb 2, 2013.
Additional material for this article may be found online
at www.jvascsurg.org.
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 6 Qadura et al 1683
Study or Subgroup
Bush23
Cao19
Garcia-Madrid22
Lifeline registry18
Moore21
Sicard20
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.09; Chi² = 6.81, df = 5 (P = .24); I² = 27%
Test for overall effect: Z = 2.19 (P = .03)
M-H, Random, 95% CI
1.53 [1.00-2.35]
4.38 [1.68-11.40]
1.77 [0.26-11.91]
0.71 [0.26-1.96]
1.55 [0.43-5.54]
1.74 [0.52-5.79]
1.66 [1.05-2.62]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
Favors Open Favors EVAR
0.1 0.2 0.5 1 2 5 10
Supplementary Fig 1 (online only). Forest plot of prospective studies comparing 30-day mortality rate after
endovascular aneurysm repair (EVAR) and open repair of unruptured abdominal aortic aneurysms (AAAs). Endo-
vascular and open repair had similar 30-day postoperative all-cause mortality. CI, Confidence interval.
Study or Subgroup
Bush23
Cao19
Garcia-Madrid22
Lifeline registry18
Moore21
Peterson28
Sicard20
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.19; Chi² = 34.15, df = 6 (P < .00001); I² = 82%
Test for overall effect: Z = 1.66 (P = .10)
M-H, Random, 95% CI
1.33 [1.03-1.71]
0.73 [0.56-0.95]
2.43 [0.58-10.09]
0.51 [0.38-0.70]
0.77 [0.47-1.26]
0.36 [0.19-0.67]
0.60 [0.36-1.01]
0.73 [0.50-1.06]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
Favors Control Favors EVAR
0.1 0.2 0.5 1 2 5 10
Supplementary Fig 2 (online only). Forest plot of prospective studies comparing long-term mortality rate after
endovascular aneurysm repair (EVAR) and open repair of unruptured abdominal aortic aneurysms (AAAs). There was
no statistical difference in long-term all-cause mortality between endovascular and open repair of AAAs. CI, Confidence
interval.
JOURNAL OF VASCULAR SURGERY
1683.e1 Qadura et al June 2013

Recommandé

Comparison of 2 ntdb studies par
Comparison of 2 ntdb studiesComparison of 2 ntdb studies
Comparison of 2 ntdb studiesnswhems
493 vues17 diapositives
Jic 2-174 par
Jic 2-174Jic 2-174
Jic 2-174Journal of Integrative Cardiology
38 vues2 diapositives
Efectividad de las_pruebas_dx tvp par
Efectividad de las_pruebas_dx tvpEfectividad de las_pruebas_dx tvp
Efectividad de las_pruebas_dx tvpguest618c545
530 vues9 diapositives
Cardiopulmonary testing preoperative par
Cardiopulmonary testing preoperativeCardiopulmonary testing preoperative
Cardiopulmonary testing preoperativeDR RML DELHI
69 vues34 diapositives
Clinical and epidemiological profile of patients undergoing total hip arthro... par
Clinical and epidemiological profile of patients undergoing  total hip arthro...Clinical and epidemiological profile of patients undergoing  total hip arthro...
Clinical and epidemiological profile of patients undergoing total hip arthro...David Sadigursky
147 vues5 diapositives

Contenu connexe

Tendances

J clin exp card predictors of ischaemia and outcomes in egyptian patients wit... par
J clin exp card predictors of ischaemia and outcomes in egyptian patients wit...J clin exp card predictors of ischaemia and outcomes in egyptian patients wit...
J clin exp card predictors of ischaemia and outcomes in egyptian patients wit...Alexandria University, Egypt
53 vues6 diapositives
nejmoa1911481.pdf par
nejmoa1911481.pdfnejmoa1911481.pdf
nejmoa1911481.pdfCarlosRonaldoQuispeE
56 vues11 diapositives
Reversal of warfarin associated coagulopathy prothrombin complex concentrates par
Reversal of warfarin associated coagulopathy prothrombin complex concentratesReversal of warfarin associated coagulopathy prothrombin complex concentrates
Reversal of warfarin associated coagulopathy prothrombin complex concentratesTÀI LIỆU NGÀNH MAY
98 vues49 diapositives
Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi... par
Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi...Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi...
Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi...Premier Publishers
100 vues6 diapositives
Effects of red blood cell transfusions on exercise tolerance and rehabilitati... par
Effects of red blood cell transfusions on exercise tolerance and rehabilitati...Effects of red blood cell transfusions on exercise tolerance and rehabilitati...
Effects of red blood cell transfusions on exercise tolerance and rehabilitati...anemo_site
341 vues5 diapositives

Tendances(20)

Reversal of warfarin associated coagulopathy prothrombin complex concentrates par TÀI LIỆU NGÀNH MAY
Reversal of warfarin associated coagulopathy prothrombin complex concentratesReversal of warfarin associated coagulopathy prothrombin complex concentrates
Reversal of warfarin associated coagulopathy prothrombin complex concentrates
Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi... par Premier Publishers
Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi...Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi...
Role of Left Ventricular Mass Index Versus Left Ventricular Relative Wall Thi...
Effects of red blood cell transfusions on exercise tolerance and rehabilitati... par anemo_site
Effects of red blood cell transfusions on exercise tolerance and rehabilitati...Effects of red blood cell transfusions on exercise tolerance and rehabilitati...
Effects of red blood cell transfusions on exercise tolerance and rehabilitati...
anemo_site341 vues
Red blood cell and at this effect of diabetes mil lute par ScSyed
Red blood cell and at this effect of diabetes mil lute Red blood cell and at this effect of diabetes mil lute
Red blood cell and at this effect of diabetes mil lute
ScSyed31 vues
ACC 2011 research highlights: A slideshow presentation par theheart.org
ACC 2011 research highlights: A slideshow presentation ACC 2011 research highlights: A slideshow presentation
ACC 2011 research highlights: A slideshow presentation
theheart.org696 vues
Retrospective Analysis of Intra Operative Blood Loss in Pelvic Oncological Su... par Premier Publishers
Retrospective Analysis of Intra Operative Blood Loss in Pelvic Oncological Su...Retrospective Analysis of Intra Operative Blood Loss in Pelvic Oncological Su...
Retrospective Analysis of Intra Operative Blood Loss in Pelvic Oncological Su...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C... par Premier Publishers
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Clinical Profile of Patients with Coronary Tortuosity and its Relation with C...
Mean platelet volume and other platelet volume indices in patients with acute... par iosrjce
Mean platelet volume and other platelet volume indices in patients with acute...Mean platelet volume and other platelet volume indices in patients with acute...
Mean platelet volume and other platelet volume indices in patients with acute...
iosrjce920 vues
Murley Meghan Thesis Female Heart Rate Variability - A Pilot Reliability Study par Meghan Murley
Murley Meghan Thesis Female Heart Rate Variability - A Pilot Reliability StudyMurley Meghan Thesis Female Heart Rate Variability - A Pilot Reliability Study
Murley Meghan Thesis Female Heart Rate Variability - A Pilot Reliability Study
Meghan Murley130 vues
A predictive model to reduce allogenic transfusions in primary total hip arth... par anemo_site
A predictive model to reduce allogenic transfusions in primary total hip arth...A predictive model to reduce allogenic transfusions in primary total hip arth...
A predictive model to reduce allogenic transfusions in primary total hip arth...
anemo_site380 vues
DU PERF SCORING par NHS
DU PERF SCORINGDU PERF SCORING
DU PERF SCORING
NHS306 vues
Leads free trial) par Iqbal Dar
Leads free trial)Leads free trial)
Leads free trial)
Iqbal Dar318 vues

Similaire à J vasc surg_review_2013

Left main disease pci vs cabg excel trial 2016 par
Left main disease   pci vs cabg excel trial 2016Left main disease   pci vs cabg excel trial 2016
Left main disease pci vs cabg excel trial 2016Kunal Mahajan
3.9K vues55 diapositives
Carotid stenosis journal club par
Carotid stenosis journal clubCarotid stenosis journal club
Carotid stenosis journal clubNeurologyKota
399 vues45 diapositives
Vasc Med-2016-Hale-1358863X15624025 par
Vasc Med-2016-Hale-1358863X15624025Vasc Med-2016-Hale-1358863X15624025
Vasc Med-2016-Hale-1358863X15624025Kayla Twomey
102 vues6 diapositives
Assessment of Intermediate Coronary Artery Lesion with Fractional Flow Reserv... par
Assessment of Intermediate Coronary Artery Lesion with Fractional Flow Reserv...Assessment of Intermediate Coronary Artery Lesion with Fractional Flow Reserv...
Assessment of Intermediate Coronary Artery Lesion with Fractional Flow Reserv...Premier Publishers
300 vues8 diapositives
ISR published par
ISR publishedISR published
ISR publishedShaikhani.
1.1K vues11 diapositives
TEE CABG JASE 2021.pdf par
TEE CABG JASE 2021.pdfTEE CABG JASE 2021.pdf
TEE CABG JASE 2021.pdfReda So
12 vues11 diapositives

Similaire à J vasc surg_review_2013(20)

Left main disease pci vs cabg excel trial 2016 par Kunal Mahajan
Left main disease   pci vs cabg excel trial 2016Left main disease   pci vs cabg excel trial 2016
Left main disease pci vs cabg excel trial 2016
Kunal Mahajan3.9K vues
Carotid stenosis journal club par NeurologyKota
Carotid stenosis journal clubCarotid stenosis journal club
Carotid stenosis journal club
NeurologyKota399 vues
Vasc Med-2016-Hale-1358863X15624025 par Kayla Twomey
Vasc Med-2016-Hale-1358863X15624025Vasc Med-2016-Hale-1358863X15624025
Vasc Med-2016-Hale-1358863X15624025
Kayla Twomey102 vues
Assessment of Intermediate Coronary Artery Lesion with Fractional Flow Reserv... par Premier Publishers
Assessment of Intermediate Coronary Artery Lesion with Fractional Flow Reserv...Assessment of Intermediate Coronary Artery Lesion with Fractional Flow Reserv...
Assessment of Intermediate Coronary Artery Lesion with Fractional Flow Reserv...
TEE CABG JASE 2021.pdf par Reda So
TEE CABG JASE 2021.pdfTEE CABG JASE 2021.pdf
TEE CABG JASE 2021.pdf
Reda So12 vues
REVIEW Stent Fractures Sfyroeras et al 2010c par Koutsiaris Aris
REVIEW  Stent Fractures Sfyroeras et al 2010cREVIEW  Stent Fractures Sfyroeras et al 2010c
REVIEW Stent Fractures Sfyroeras et al 2010c
Koutsiaris Aris367 vues
Cardiac Surgery in Nonagenarians: An Institutional 20 Year Experience par JohnJulie1
Cardiac Surgery in Nonagenarians: An Institutional 20 Year ExperienceCardiac Surgery in Nonagenarians: An Institutional 20 Year Experience
Cardiac Surgery in Nonagenarians: An Institutional 20 Year Experience
JohnJulie13 vues
Cardiac Surgery in Nonagenarians: An Institutional 20 Year Experience par suppubs1pubs1
Cardiac Surgery in Nonagenarians: An Institutional 20 Year ExperienceCardiac Surgery in Nonagenarians: An Institutional 20 Year Experience
Cardiac Surgery in Nonagenarians: An Institutional 20 Year Experience
suppubs1pubs125 vues
Cardiac Surgery in Nonagenarians: An Institutional 20 Year Experience par suppubs1pubs1
Cardiac Surgery in Nonagenarians: An Institutional 20 Year ExperienceCardiac Surgery in Nonagenarians: An Institutional 20 Year Experience
Cardiac Surgery in Nonagenarians: An Institutional 20 Year Experience
suppubs1pubs158 vues
Antegrage cerebral perfusion par mshihatasite
Antegrage cerebral perfusionAntegrage cerebral perfusion
Antegrage cerebral perfusion
mshihatasite1.5K vues
Identifying the Best Candidates for Primary Tumour Resection Among Patients w... par eshaasini
Identifying the Best Candidates for Primary Tumour Resection Among Patients w...Identifying the Best Candidates for Primary Tumour Resection Among Patients w...
Identifying the Best Candidates for Primary Tumour Resection Among Patients w...
eshaasini3 vues
ClinicalOutcomesFollowingCoronary BifurcationPCITechniques.pdf par Irving Torres Lopez
ClinicalOutcomesFollowingCoronary BifurcationPCITechniques.pdfClinicalOutcomesFollowingCoronary BifurcationPCITechniques.pdf
ClinicalOutcomesFollowingCoronary BifurcationPCITechniques.pdf
Protocol For Endovasc Repair Of Rupture A A par Ahmed Shalabi
Protocol For Endovasc Repair Of Rupture  A AProtocol For Endovasc Repair Of Rupture  A A
Protocol For Endovasc Repair Of Rupture A A
Ahmed Shalabi624 vues

Plus de samirsharshar

Architecte de pole par
Architecte de poleArchitecte de pole
Architecte de polesamirsharshar
630 vues94 diapositives
Bja 2015 114(4) par
Bja 2015 114(4)Bja 2015 114(4)
Bja 2015 114(4)samirsharshar
704 vues11 diapositives
Aa 2014 119-5 par
Aa 2014 119-5Aa 2014 119-5
Aa 2014 119-5samirsharshar
567 vues10 diapositives
Vademecum prise en charge périanesthésique par
Vademecum prise en charge périanesthésiqueVademecum prise en charge périanesthésique
Vademecum prise en charge périanesthésiquesamirsharshar
667 vues4 diapositives
Vademecum du M.A.R. par
Vademecum du M.A.R.Vademecum du M.A.R.
Vademecum du M.A.R.samirsharshar
790 vues7 diapositives
Manifeste et Code du Service d'Anesthésie par
Manifeste et Code du Service d'AnesthésieManifeste et Code du Service d'Anesthésie
Manifeste et Code du Service d'Anesthésiesamirsharshar
1K vues28 diapositives

Plus de samirsharshar(20)

Vademecum prise en charge périanesthésique par samirsharshar
Vademecum prise en charge périanesthésiqueVademecum prise en charge périanesthésique
Vademecum prise en charge périanesthésique
samirsharshar667 vues
Manifeste et Code du Service d'Anesthésie par samirsharshar
Manifeste et Code du Service d'AnesthésieManifeste et Code du Service d'Anesthésie
Manifeste et Code du Service d'Anesthésie
samirsharshar1K vues
Thiruvenkatarajan et al-2015-anaesthesia par samirsharshar
Thiruvenkatarajan et al-2015-anaesthesiaThiruvenkatarajan et al-2015-anaesthesia
Thiruvenkatarajan et al-2015-anaesthesia
samirsharshar562 vues
N8rskov et al-2014-anaesthesia par samirsharshar
N8rskov et al-2014-anaesthesiaN8rskov et al-2014-anaesthesia
N8rskov et al-2014-anaesthesia
samirsharshar418 vues
Lankhorst et al-2015-anaesthesia par samirsharshar
Lankhorst et al-2015-anaesthesiaLankhorst et al-2015-anaesthesia
Lankhorst et al-2015-anaesthesia
samirsharshar322 vues
Heesen et al-2015-anaesthesia par samirsharshar
Heesen et al-2015-anaesthesiaHeesen et al-2015-anaesthesia
Heesen et al-2015-anaesthesia
samirsharshar320 vues
Wijeysundera et al-2015-anesthesia_&_analgesia par samirsharshar
Wijeysundera et al-2015-anesthesia_&_analgesiaWijeysundera et al-2015-anesthesia_&_analgesia
Wijeysundera et al-2015-anesthesia_&_analgesia
samirsharshar315 vues
Warner 2015-anesthesia &-analgesia par samirsharshar
Warner 2015-anesthesia &-analgesiaWarner 2015-anesthesia &-analgesia
Warner 2015-anesthesia &-analgesia
samirsharshar291 vues
Terrando et al-2015-anesthesia_&_analgesia par samirsharshar
Terrando et al-2015-anesthesia_&_analgesiaTerrando et al-2015-anesthesia_&_analgesia
Terrando et al-2015-anesthesia_&_analgesia
samirsharshar416 vues
Shafer 2015-anesthesia &-analgesia par samirsharshar
Shafer 2015-anesthesia &-analgesiaShafer 2015-anesthesia &-analgesia
Shafer 2015-anesthesia &-analgesia
samirsharshar327 vues
Schulz st%f cbner-2015-anesthesia-&_analgesia par samirsharshar
Schulz st%f cbner-2015-anesthesia-&_analgesiaSchulz st%f cbner-2015-anesthesia-&_analgesia
Schulz st%f cbner-2015-anesthesia-&_analgesia
samirsharshar376 vues
Lee et al-2015-anesthesia_&_analgesia par samirsharshar
Lee et al-2015-anesthesia_&_analgesiaLee et al-2015-anesthesia_&_analgesia
Lee et al-2015-anesthesia_&_analgesia
samirsharshar392 vues
Koch 2015-anesthesia &-analgesia par samirsharshar
Koch 2015-anesthesia &-analgesiaKoch 2015-anesthesia &-analgesia
Koch 2015-anesthesia &-analgesia
samirsharshar954 vues
Kancir et al-2015-anesthesia_&_analgesia par samirsharshar
Kancir et al-2015-anesthesia_&_analgesiaKancir et al-2015-anesthesia_&_analgesia
Kancir et al-2015-anesthesia_&_analgesia
samirsharshar676 vues

Dernier

Antimalarial agents par
Antimalarial agentsAntimalarial agents
Antimalarial agentsDr. Ajmer Singh Grewal
41 vues84 diapositives
Gastro-retentive drug delivery systems.pptx par
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptxABG
242 vues32 diapositives
Macrolide antibiotics par
Macrolide antibioticsMacrolide antibiotics
Macrolide antibioticsDr. Ajmer Singh Grewal
16 vues40 diapositives
Quit Smoking Revolution.pdf par
Quit Smoking Revolution.pdfQuit Smoking Revolution.pdf
Quit Smoking Revolution.pdfGio Ferrandino
29 vues56 diapositives
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx par
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxABG
122 vues40 diapositives
functional gait assessment.pdf par
functional gait assessment.pdffunctional gait assessment.pdf
functional gait assessment.pdfmhmad farooq
10 vues3 diapositives

Dernier(20)

Gastro-retentive drug delivery systems.pptx par ABG
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptx
ABG242 vues
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx par ABG
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
ABG122 vues
functional gait assessment.pdf par mhmad farooq
functional gait assessment.pdffunctional gait assessment.pdf
functional gait assessment.pdf
mhmad farooq10 vues
NeuroGASTRO-2023-Programme.pdf par OanaTimofte3
NeuroGASTRO-2023-Programme.pdfNeuroGASTRO-2023-Programme.pdf
NeuroGASTRO-2023-Programme.pdf
OanaTimofte313 vues
Trustlife Türkiye - Güncel Platform Yapısı par Trustlife
Trustlife Türkiye - Güncel Platform YapısıTrustlife Türkiye - Güncel Platform Yapısı
Trustlife Türkiye - Güncel Platform Yapısı
Trustlife53 vues
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad par Swetha rani Savala
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
Fetal and Neonatal Circulation - MBBS, Gandhi medical College Hyderabad
CCDI Kibbe Wake Forest University Dec 2023.pptx par Warren Kibbe
CCDI Kibbe Wake Forest University Dec 2023.pptxCCDI Kibbe Wake Forest University Dec 2023.pptx
CCDI Kibbe Wake Forest University Dec 2023.pptx
Warren Kibbe20 vues
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx par ABG
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptxICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx
ICH AND WHO GUIDELINES FOR VALIDATION OF EQUIPMENTS.pptx
ABG73 vues
Prof. Dame Louise Robinson - Future of Ageing 2023 par ILCUK
Prof. Dame Louise Robinson - Future of Ageing 2023Prof. Dame Louise Robinson - Future of Ageing 2023
Prof. Dame Louise Robinson - Future of Ageing 2023
ILCUK37 vues
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP par MohamadAlhes
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDPChronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP
MohamadAlhes122 vues
Pulmonary arterial hypertension (PAH).pptx par dralialhayali
Pulmonary arterial hypertension (PAH).pptxPulmonary arterial hypertension (PAH).pptx
Pulmonary arterial hypertension (PAH).pptx
dralialhayali14 vues

J vasc surg_review_2013

  • 1. REVIEW ARTICLES Richard P. Cambria, MD, Section Editor From the Canadian Society for Vascular Surgery Mortality and reintervention following elective abdominal aortic aneurysm repair Mohammad Qadura, MD, PhD,a Farhan Pervaiz, BSc,a John A. Harlock, MD, FRCSC,a Ashraf Al-Azzoni, MD,b Forough Farrokhyar, PhD,c,d Kamyar Kahnamoui, MD, MHRM,c,d David A. Szalay, MD, MEd, FRCSC,a and Theodore Rapanos, MD, MSc, FRCSC,a Hamilton, Ontario, Canada Background: The objective of this study is to provide an up-to-date meta-analysis on the short- and long-term mortality rates of elective repair of abdominal aortic aneurysms (AAAs) via the open and endovascular approaches. Methods: MEDLINE, EMBASE, and Cochrane Central Register of Controlled trials, conference proceeding from major vascular meetings were searched for randomized trials comparing open vs elective endovascular aneurysm repair (EVAR) of AAAs. A random-effects model was used for analysis. Risk ratio (RR) and 95% confidence intervals (CIs) of open vs EVAR were calculated for short- and long-term mortality and reintervention rates. Results: The analysis encompassed four randomized controlled trials with a total of 2783 patients. The open repair group resulted in significantly increased 30-day postoperative all-cause mortality compared with EVAR repair group (3.2% vs 1.2%; RR, 2.81; 95% CI, 1.60-4.94); however, there is no statistical difference in the long-term all-cause mortality between both groups (RR, 0.97; 95% CI, 0.86-1.10). Interestingly, fewer patients underwent reintervention procedures in the open repair group compared with those who had EVAR repair (9.3% vs 18.9%; RR, 0.49; 95% CI, 0.40-0.60), but this finding is doubtful due to the large heterogeneity. Lastly, no statistical difference in long-term mortality rates attributable to cardiovascular disease (CVD), aneurysm related, or stroke were found between the two types of repair. Conclusions: Results of this meta-analysis demonstrate that the 30-day all-cause mortality rate is higher with open than with EVAR repair; however, there is no statistical difference in the long-term all-cause and cause-specific mortality between both groups. The reintervention rate attributable to procedural complication was higher in the EVAR group. Because of the equivalency of long-term outcomes and the short-term benefits of EVAR, an endovascular-first approach to AAAs can be supported by the meta-analysis. (J Vasc Surg 2013;57:1676-83.) As a frequent cause of cardiovascular mortality, abdom- inal aortic aneurysms (AAAs) place a significant burden on health care systems in developed nations.1,2 Recent studies have shown a prevalence of AAA as high as 9% in people 65-85 years of age.2 The risk of rupture, which is fatal in 65% of individuals, is directly correlated with the aneu- rysm’s diameter.3 Surgical intervention is currently the accepted standard used to prevent mortality from aneurysm rupture. This can be approached from either a standard open technique or an endovascular procedure with a stent graft system. The open approach, practiced by surgeons for over 50 years, had been the treatment of choice until a less invasive alternative, endovascular aneurysm repair (EVAR), was developed.4 With similar indications for both approaches, deciding on an elective repair method can be very challenging. Several trials have compared the EVAR and open approaches, focusing on their effectiveness and outcomes. However, there are still some controversies in the literature on the short- and long-term mortality rates of these approaches.2 Our goal is to review the current evidence comparing the open and EVAR approaches for AAA repair by performing a meta-analysis of all the randomized controlled trials that compared both approaches with regard to their effectiveness and safety. METHODS Design. A systematic review and meta-analysis of randomized clinical trials were conducted. Outcome of interest. The primary outcome of interest was short- and long-term all-cause mortality. We considered mortality within 30 days after the operation to represent the short-term mortality rate, whereas mortality From the Division of Vascular Surgery,a Division of Cardiology,b Division of General Surgery,c and Department of Clinical Epidemiology and Bio- statistics,d McMaster University. Author conflict of interest: none. Presented at the Thirty-fourth Annual Meeting of the Canadian Society for Vascular Surgery, Quebec City, Quebec, Canada, September 28-29, 2012. Additional material for this article may be found online at www.jvascsurg.org. Reprint requests: John A. Harlock, MD, FRCSC, Division of Vascular Surgery, McMaster University, Hamilton General Hospital, 237 Barton St E, Hamilton, Ontario, Canada L8L 2X2 (e-mail: harlocj@mcmaster.ca). The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest. 0741-5214/$36.00 Copyright Ó 2013 by the Society for Vascular Surgery. http://dx.doi.org/10.1016/j.jvs.2013.02.013 1676
  • 2. beyond the 2-year mark was considered to represent the long-term mortality rate. Secondary outcomes of interest included cardiovascular-related death, aneurysm-related death, and reintervention rates. Criteria for study selection. All randomized controlled trials comparing the mortality rates of EVAR vs open AAA repair were included. Study selection included randomized controlled trials (RCTs) published until 2012 that (1) enrolled patients for elective repair of AAAs with a size $5 cm or AAAs of 4.5 cm that are rapidly enlarging; (2) all patients were good surgical candi- dates; and (3) the studies reported all-cause mortality Table I. Description of the included trials (RCTs) Source Age, mean 6 SD, years Number of patients Inclusion criteria Key exclusion criteria Follow- up durationOpen EVAR Open EVAR ACE 20111 70 6 7.1 68.9 6 7.7 148 150 (1) CT scan finding: AAA >50 mm in men, >45 mm in women, common iliac artery aneu- rysm >30 mm (2) Upper neck free of major thrombus or calcification (3) $15 mm in length (4) Angle between neck and axis of aneurysm <60 mm (5) Clinical assessment graded patients in categories of 0-2 according to comorbidity score of SVS/AAVS (1) Previous AAA surgery (2) Ruptured aneurysm (3) Mycotic aneurysm (4) Severe iodine allergy (5) Life expectancy deemed <6 months (6) Category 3 of SVS/AAVS 4.8 years DREAM 201014 69.6 þ 6.8 70.7 þ 6.6 178 173 (1) Elective repair (2) AAA size >5 cm (3) Suitable for operation as per cardiology/inter- nist for open and endograft- dependent anatomic criteria for EVAR (1) Emergency repair (2) Inflammatory aneurysm (3) Anatomic variation (4) Connective tissue disease (5) History of organ transplant (6) Life expectancy less than 2 years 6.4 years EVAR 112 2011 74.1 6 6.1 74.1 6 6.1 626 626 (1) Elective repair (2) AAA >5.5 cm (3) Surgical candidate (4) Age >60 years NA 8 years OVER15 2009 70.5 6 7.8 69.6 6 7.8 437 444 (1) Elective repair (2) AAA >5 cm (3) AAA of 4.5 cm and a rapidly enlarging aneurysm (4) Surgical candidate (5) An associated iliac aneurysm with a maximum diam- eter of at least 3 cm (1) Previous abdominal aortic surgery (2) Needed urgent report. Unwilling or unable to give informed consent or follow the protocol 2 years AAVS, American Association for Vascular Surgery; AAA, abdominal aortic aneurysm; ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endo- prothése; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom Endovascular Aneurysm Repair 1; NA, not available; OVER, Open Versus Endovascular Repair; RCT, randomized controlled trial; SVS, Society for Vascular Surgery. JOURNAL OF VASCULAR SURGERY Volume 57, Number 6 Qadura et al 1677
  • 3. (short-term/long-term), aneurysm-related mortality, car- diovascular disease (CVD)-related mortality (including congestive heart failure, myocardial infarction, cardiac arrest), stroke-related mortality, and surgical reintervention rates. We excluded RCTs that had (1) patients with previous abdominal aortic surgery, (2) patients who needed urgent surgery for ruptured AAAs; (3) patients unwilling or unable to give informed consent or follow the protocol; and (4) studies with a mean follow-up of less than 2 years. Literature search and study selection. Studies were identified by electronic literature searches in the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE from 1988 to 2012 using combinations of the following terms: aortic graft, endovascular, EVAR, open, abdominal aortic aneurysm, AAA, and repair. We also con- tacted trials’ authors for further data as needed. Our litera- ture search also included reviewing the references of recent articles published on this topic including the issues from the past 12 months of the Journal of Vascular Surgery. All available data were utilized including full publications, abstracts, and online late breaking presentations. We identi- fied 2245 reports that were reviewed by two independent reviewers (M.Q., F.P.); a third reviewer (T.R.) settled any discrepancies. A previous meta-analysis was published on this topic; however, this meta-analysis does not include the results from the most recent RCTs.5 We also did an analysis of a number of prospective RCTs but did not include these in our meta-analysis as per the inclusion criteria. Data collection. Two authors (M.Q., F.P.) indepen- dently identified the trials for inclusion and exclusion criteria as mentioned above. For all published trials, the following information was tabulated according to the randomization group by two authors (M.Q., F.P.): (1) information about the trial’s clinical characteristics, the number of participating patients, mean age, and duration of clinical follow-up (Table I); and (2) aneurysm related mortality, CVD related mortality (including congestive heart failure, myocardial infarction, cardiac arrest), stroke related mortality, surgical reintervention rates, short-term all-cause mortality (<30 days) and long-term mortality (>2 years with short-term deaths excluded). If no resolu- tion of agreement was achieved between the reviewers, a senior author (T.R.) was consulted to settle the discrep- ancy. The level of agreement between the two authors (M.Q., F.P.) varied from 83% to 100%. Assessment of quality and risk of bias. The risk of bias was assessed according to the guidelines of The Cochrane Collaboration tool for assessing risk of bias.6-11 The assessment of risk of bias in the trials was based on consequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incom- plete outcome data; selective outcome reporting; and other sources of bias such as baseline imbalance, early stopping bias, academic bias, and source of funding bias.6 M.Q. and F.P. assessed the risk of bias in all trials with a third reviewer (T.R.) to settle any discrepancies. Statistical analysis. The reliability between the two reviewers for literature search, kappa score for the included/excluded studies, data collection, and quality assessment was measured using kappa statistics and SPSS software (IBM, Armonk, NY). For dichotomous outcomes, risk ratio (RR) of open vs EVAR repair with confidence intervals (CIs) and P value are reported. Results were considered statistically significant at P # .05. Because of the possibility of a small number of studies and between- study heterogeneity, the pooled RR was calculated with the Mantel-Haenszel method for random effects.6 A random- effects model meta-analysis assumes that the true under- lying effects vary between trials. An intention-to-treat analysis was performed by using the same end point defi- nitions as in the primary studies. To assess heterogeneity across trials, we used the Cochrane c2 test based on the pooled RR. Heterogeneity was considered statistically significant at P # .1 because the heterogeneity test is underpowered when small numbers of studies are included. Also, the I2 statistic was used to quantify heterogeneity; a value of <25% is considered small heterogeneity, a value of 25%-50% is considered as moderate heterogeneity, whereas a value >50% is considered as a large heteroge- neity.6 Cochrane c2 statistic with P value and I2 value are reported. A funnel plot is used to explore publication bias,6 but it is not recommended for less than 10 studies because asymmetry could appear because of chance.12 Review Manager, v. 5.0 (Cochrane Collaboration, Copenhagen, Denmark), was used to generate the forest plots and RRs. RESULTS Our search identified 2245 abstracts. After review of the abstracts, we identified four randomized controlled trials that met our inclusion criteria (Fig 1). All were pub- lished within the past 4 years. All of the presented results in this study summarize the findings from the RCTs. None of the studies was blinded. The Cohen’s k scores for the interobserver reliabilities for the literature search process and quality assessment are Fig 1. Literature research for selected studies. JOURNAL OF VASCULAR SURGERY 1678 Qadura et al June 2013
  • 4. 0.88, and 0.9, respectively. The data harvest level of agree- ment among M.Q. and F.P. varied from 83% to 100%. The literature review also yielded a study by P. W. M. Cuypers et al 2001.13 However, we have decided not to include this study in the calculations that are presented. This article did not elicit the data necessary for our system- atic review. The only outcome measure presented was short-term all-cause mortality. The mortality was not sub- divided by cause, which makes it difficult to compare with the other studies included in this meta-analysis. To determine if the exclusion of this study skews the results, short-term mortality and all-cause mortality were calcu- lated including this study. The results showed that the inclusion or exclusion of this study did not alter the overall outcome (data not shown). Our literature review identified four trials that are used in our analysis. These studies reported outcomes of open repair vs EVAR repair of AAAs in patients who were candi- dates for both procedures (n ¼ 2783).1,14-17 Table II summarizes the characteristics of the four RCTs that evalu- ated AAA repair. Sample size varied from 298 to 1252 with a similar number of participants in study groups. The mean age varied from 69 to 74 years, but it was similar between the groups for all studies. The mean follow-up time varied from 2 years (United Kingdom Endovascular Aneu- rysm Repair 1 [EVAR 1], 2011) to 8 years (Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése [ACE], 2011), but all reported 30-day mortality as short term. The loss to follow-up for the ACE, Dutch Random- ized Endovascular Aneurysm Repair (DREAM), EVAR 1, and Open Versus Endovascular Repair (OVER) studies was small: 8, 0, 17, and 2 patients, respectively. Fig 2 shows a significant increased 30-day postopera- tive all-cause mortality in open repair compared with EVAR repair (3.2% vs 1.2%; RR, 2.81; 95% CI, 1.60- 4.94). Findings were consistent across the studies. The between-study heterogeneity was of small size (I2 ¼ 23%). We also compared the long-term all-cause mortality between open and EVAR repair. As shown in Fig 3, there is no statistically significant difference in the long-term all- cause mortality between open and EVAR repair. RR was 0.95 (95% CI, 0.84-1.10) with no heterogeneity. A comparison of reintervention rates in both groups was conducted and summarized in Fig 4. Although there was no statistical difference in the long-term all-cause mortality, it is shown in Fig 4 that reintervention proce- dures in the open repair group were 50% lower than in the EVAR repair group (9.3% vs 18.9%; RR, 0.49; 95% Table II. The assessment of risk of bias in the trials was based on sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias such as baseline imbalance, early stopping bias, academic bias, and source of funding bias Bias DREAM EVAR 1 OVER ACE Sequence generation Low Moderate Moderate High Allocation concealment Low Low Low Low Blinding participants and personnel Moderate-high Moderate-high Moderate-high Moderate-high Blinding outcome assessment Moderate-high Moderate-high Moderate-high Moderate-high Incomplete outcome data Low Low Low High Selective outcome reporting Low Low Low Low Other sources Moderate Low Low Low ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair. Study or Subgroup ACE1 DREAM16 EVAR 114 OVER17 Total (95% CI) Total events Heterogeneity: Tau² = 0.18; Chi² = 3.90, df = 3 (P = .27); I² = 23% Test for overall effect: Z = 2.45 (P = .01) M-H, Random, 95% CI 0.50 [0.05-5.49] 3.89 [0.84-18.05] 2.36 [1.18-4.74] 10.16 [1.31-79.03] 2.72 [1.22-6.08] oitaRksiRoitaRksiR M-H, Random, 95% CI Favors Open Favors EVAR 0.01 0.1 1 10 100 Fig 2. Forest plot of randomized trials comparing 30-day mortality rate after endovascular aneurysm repair (EVAR) and open repair of unruptured abdominal aortic aneurysms (AAAs). Endovascular in comparison to open repair has a lower 30-day postoperative all-cause mortality. ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése; CI, confidence interval; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair. JOURNAL OF VASCULAR SURGERY Volume 57, Number 6 Qadura et al 1679
  • 5. CI, 0.40-0.60). However, the large between-study hetero- geneity of 82% undermines the validity of pooled RR for reintervention. The long-term mortality was further divided by cause (cardiovascular, aneurysm related and stroke), and these were compared in both groups. Fig 5, A-C demonstrate no statistical difference in long-term mortality rates due to CVD, aneurysm related and stroke after EVAR or open repair of AAAs. CVD (RR, 0.9; 95% CI, 0.6-1.2) and stroke (RR, 0.9; 95% CI, 0.5-1.6) were in favor of open repair, but aneurysm-related deaths were (RR, 1.1; 95% CI, 0.5-2.5) were in favor of EVAR repair. Heteroge- neity (I2 ¼ 47%) of close to moderate size was present for aneurysm-related deaths that might be attributable to the small number of events in ACE 2011 and DREAM 2010 trials. We have also refined our literature search to include nonrandomized prospective studies that compared the short- and long-term mortality events post-EVAR and open repair of AAAs.18-23 Unlike the results we obtained from RCT studies, the analysis of the prospective studies showed no statistical difference in the short-term all-cause mortality between open repair and EVAR repair (RR, 1.66; 95% CI, 1.05-2.62). The results from the long-term all-cause mortality from prospective cohort studies were not reliable because of the large between- study heterogeneity (80%). Hatala et al24 recommended not to pool the results when heterogeneity is larger than 50%. The analysis of the prospective cohort studies showed no statistical difference in the long-term all-cause mortality between open repair and EVAR repair (RR, 0.75; 95% CI, 0.53, 1.06). DISCUSSION These results represent an up-to-date meta-analysis of the randomized trials for comparing open vs EVAR repair of AAAs. Open repair has long been accepted as the gold standard repair for AAAs because of its acceptable low risk, predictability for expected outcomes, and durability. EVAR has been established to help reduce short-term Study or Subgroup ACE1 DREAM16 EVAR 114 OVER17 Total (95% CI) Total events Heterogeneity: Tau² = 0.00; Chi² = 0.91, df = 3 (P = .82); I² = 0% Test for overall effect: Z = 0.45 (P = .65) M-H, Random, 95% CI 0.73 [0.35-1.54] 0.93 [0.68-1.28] 0.98 [0.85-1.12] 1.11 [0.67-1.85] 0.97 [0.86-1.10] oitaRksiRoitaRksiR M-H, Random, 95% CI Favors Open Favors EVAR 0.5 0.7 1 1.5 2 Fig 3. Forest plot of randomized trials comparing long-term mortality rate after endovascular aneurysm repair (EVAR) and open repair of unruptured abdominal aortic aneurysms (AAAs). There was no statistical difference in long-term all- cause mortality between endovascular and open repair of AAAs. ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése; CI, confidence interval; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair. Study or Subgroup ACE1 DREAM16 EVAR 114 OVER17 Total (95% CI) Total events Heterogeneity: Tau² = 0.21; Chi² = 16.44, df = 3 (P = .0009); I² = 82% Test for overall effect: Z = 2.71 (P = .007) M-H, Random, 95% CI 0.17 [0.06-0.47] 0.61 [0.41-0.91] 0.38 [0.28-0.51] 0.88 [0.59-1.32] 0.49 [0.29-0.82] oitaRksiRoitaRksiR M-H, Random, 95% CI Favors Open Favors EVAR 0.05 0.2 1 5 20 Fig 4. Forest plot of randomized trials comparing reintervention rates after endovascular aneurysm repair (EVAR) or open repair of unruptured abdominal aortic aneurysms (AAAs). Open in comparison to endovascular repair has a lower reintervention rate. ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése; CI, confidence interval; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair. JOURNAL OF VASCULAR SURGERY 1680 Qadura et al June 2013
  • 6. mortality associated with elective AAA repair.17 These initial benefits of EVAR, though, are not sustained on longer-term follow-up as confirmed with the EVAR 1, DREAM, and OVER trials as shown in this current meta-analysis. The French ACE trial found different results when it came to perioperative outcomes, as no early survival advantage was attributed to EVAR compared with open repair. They also found that in low-risk patients, open repair was as safe as EVAR, but with less reinterventions. As demonstrated on most of the trials, the reinterven- tion rate was higher in the EVAR group of patients. The DREAM and OVER trials appear to have counted reinter- vention rates for open and EVAR patients as graft-related indications, wound-related indications (incisional hernia and wound infection), and local or systemic indications (bleeding, endoleak, and small bowel obstructions). The EVAR 1 and ACE trials appear to have counted reinterven- tion rates for open and EVAR patients as graft-related interventions including graft rupture, endoleak, para- anastomotic aneurysm, graft replacement, and graft occlu- sions/stenoses. The lifetime need for reintervention in patients who undergo an EVAR repair approaches 20%. The OVER trial, though, considered more specifically surgical complications than both the DREAM and EVAR 1 trials and recorded a 5% rate of patients needing incisional hernia repairs. As such, OVER did not demonstrate a differ- ence for reintervention rate between the types of repair. In Study or Subgroup ACE1 DREAM16 EVAR 114 OVER17 Total (95% CI) Total events Heterogeneity: Tau² = 0.00; Chi² = 1.54, df = 2 (P = .46); I² = 0% Test for overall effect: Z = 0.64 (P = .52) M-H, Random, 95% CI Not estimable 1.05 [0.51-2.16] 0.93 [0.66-1.32] 0.45 [0.14-1.46] 0.91 [0.67-1.23] oitaRksiRoitaRksiR M-H, Random, 95% CI Favors Open Favors EVAR Study or Subgroup ACE1 DREAM16 EVAR 114 OVER17 Total (95% CI) Total events Heterogeneity: Tau² = 0.28; Chi² = 5.67, df = 3 (P = .13); I² = 47% Test for overall effect: Z = 0.26 (P = .80) M-H, Random, 95% CI 0.17 [0.02-1.38] 2.92 [0.12-71.10] 1.00 [0.69-1.45] 2.20 [0.84-5.74] 1.11 [0.50-2.46] oitaRksiRoitaRksiR M-H, Random, 95% CI Favors Open Favors EVAR Study or Subgroup DREAM16 EVAR 114 Total (95% CI) Total events Heterogeneity: Tau² = 0.00; Chi² = 0.32, df = 1 (P = .57); I² = 0% Test for overall effect: Z = 0.46 (P = .64) M-H, Random, 95% CI 1.30 [0.29-5.71] 0.82 [0.44-1.51] 0.88 [0.50-1.54] oitaRksiRoitaRksiR M-H, Random, 95% CI Favors Open Favors EVAR A B C 0.1 0.2 0.5 1 2 5 10 0.01 0.1 1 10 100 0.1 0.2 0.5 1 2 5 10 Fig 5. Forest plot of randomized trials comparing long-term mortality rates due to cardiovascular disease (CVD) (A), aneurysm related (B), and stroke (C) after endovascular aneurysm repair (EVAR) or open repair of unruptured abdominal aortic aneurysms (AAAs), respectively. There is no statistical difference in long-term mortality rates because of CVD, aneurysm related and stroke after EVAR, or open repair of AAAs. ACE, Anévrisme de L’aorte Abdominale: Chirurgie versus Endoprothése; CI, confidence interval; DREAM, Dutch Randomized Endovascular Aneurysm Repair; EVAR 1, United Kingdom Endovascular Aneurysm Repair 1; OVER, Open Versus Endovascular Repair. JOURNAL OF VASCULAR SURGERY Volume 57, Number 6 Qadura et al 1681
  • 7. the ACE trial, there was a statistically significant difference when it came to wound complications between the open surgical repair and EVAR arms with 25% of patients under- going open repair having complications vs 0.7% in the EVAR group. The ACE trial lists did not specifically record the incidence of abdominal wall reconstruction or incisional repairs following open repair group. The incidence of bowel obstruction associated with open surgery was also not re- ported. This may have affected the outcomes of their stated reintervention rate, such as with the OVER trial, as we know that incisional complications following open repair for AAA are not negligible.25 The weight of the ACE trial, though, did not bear out in the Forest plot to affect the overall swing toward EVAR as requiring a higher rate of reintervention. This trend is also echoed in the EURO- STAR registry in which there was an overall 14% reinterven- tion rate, with complications occurring more frequently in AAAs >5.5 cm.26 In this current meta-analysis, we found a higher risk of reintervention for EVAR compared with open repair. However, the large heterogeneity between studies undermines the validity of the pooled RR for reinter- vention. This large heterogeneity might be due to the definition of and the reasons for reintervention that might differ from study to study. In performing this meta-analysis, we were able to look at the current RCT literature for open vs EVAR repair as a whole. Any initial benefit that was gained with an EVAR approach was lost on longer-term follow-up in these studies. There is no statistical difference in the long-term mortality comparing open vs EVAR repair. This might be due to the fact that the length of follow-up varied between studies from 2 to 8 years. Further study of long-term mortality by listed cause demonstrates no difference when comparing either CVD- related mortality, aneurysm-related mortality, or stroke- related mortality. This is not overly surprising, as those who survive the initial periprocedural period often return back to their baseline risk, independent of type of proce- dure for AAA repair. Based on this meta-analysis, we are able to demonstrate the short-term mortality benefits of an EVAR approach. For those patients with a life expectancy <2 years, an indi- vidualized treatment plan is prudent and thoughtful discus- sion with the patient in regard to overall goals of care should be had, based on the results of the EVAR 2 trial.27 This group of patients that were deemed unfit to undergo open AAA repair were not included in our meta-analysis based on our inclusion criteria. Although most patients in the DREAM, OVER, and EVAR 1 were fit for surgery, baseline characteristics may not be fully identical, and a similar distribution of risk factors does not fully take into account the association of risks. The OVER trial used the Research ANd Develop- ment (RAND) surgical risk score with 53% patients consid- ered as low risk for surgery. However, the risk assessment of patients in the EVAR 1 or DREAM was left to each center’s appreciation. This difference in patient risk assess- ment may account for the heterogeneity in clinical findings between the different studies. The ACE trial looked at patients who were low to moderate risk for undergoing surgical repair and excluded patients who had a life expec- tancy of less than 6 months, or were in category 3 of the Society for Vascular Surgery/American Association for Vascular Surgery comorbidity score for the clinical assess- ment. These differences might account for the between- study heterogeneity for 30-day postoperative mortality. As with any meta-analysis, the results depend on the quality and quantity of the studies that were included in the analysis. Here, the four major randomized controlled trials for EVAR open repairs have been analyzed, as they met our search criteria. This includes over 2700 patients randomized. Other prospective studies were excluded, as they did not meet our full criteria of randomized trials or reporting of outcomes beyond 2 years. This does limit our breadth of studies captured but does help to create a clearer picture with similar patient groups. Although, as discussed in our Results section, the inclusion of a number of prospec- tive nonrandomized trials reaffirms the long-term mortality equivalency of EVAR and open repairs, but also found a similar short-term equivalency. These results are inter- esting and confirm our data for long-term morality. The difference in the short-term mortality between prospective studies and RCTs can be attributed to the lack of random- ization and selection bias of patients. These studies might have recruited younger patients with few comorbidities who are better fit to undergo an open repair and the older patients, or those with more medical comorbidities to undergo an endovascular repair. Therefore, we must analyze the prospective studies with caution since they are prone to selection bias and information bias. Also, because of the lack of randomization, a higher potential for con- founding factors can sometimes be observed in prospective studies. The strength of this systematic review and meta- analysis is that any potential biases for search strategy, inclusion and exclusion of the studies, and data collection are minimized by an independent review process. Also, only randomized controlled trials are included, appropriate statistical methods are used and study heterogeneity is accounted for in the analysis. The weakness of this study is the small number of the included studies; we, however, ensured that all eligible studies were included and our sepa- rate analysis of nonrandomized prospective trials did not add much to the conclusions drawn. CONCLUSIONS Through this meta-analysis, we are able to confer with most recent studies on EVAR for AAAs. EVAR reduces the short-term mortality associated with surgical repair, but this benefit is not sustained on longer-term follow-up. It is also confirmed that the reintervention rate was higher with an EVAR repair. This is an up-to-date review of the most recent randomized controlled trials comparing open with EVAR repair for AAAs. This meta-analysis supports the notion of an endovascular-first approach to AAAs JOURNAL OF VASCULAR SURGERY 1682 Qadura et al June 2013
  • 8. attributable to the short-term benefit of EVAR and the long-term mortality equivalency. AUTHOR CONTRIBUTIONS Conception and design: MQ, FP, AA, JH Analysis and interpretation: MQ, FP, AA, JH, FF, KK, DS Data collection: MQ, FP Writing the article: MQ, FP, AA, FF, JH Critical revision of the article: MQ, JH, FF, KK, DS Final approval of the article: MQ, DS, JH Statistical analysis: MQ, FF, KK Obtained funding: Not applicable Overall responsibility: JH REFERENCES 1. Becquemin JP, Pillet JC, Lescalie F, Sapoval M, Goueffic Y, Lermusiaux P, et al. A randomized controlled trial of endovascular aneurysm repair versus open surgery for abdominal aortic aneurysm in low-to-moderate-risk patients. J Vasc Surg 2011;53:1167-73. 2. Sakalihasan N, Limet R, Defaw OD. Abdominal aortic aneurysm. Lancet 2005;365:1577-89. 3. Kniemeyer HW, Kessler T, Reber PU, Ris HB, Hakki H, Widmer MK. Treatment of ruptured abdominal aortic aneurysm, a permanent chal- lenge or a waste of resources? Prediction of outcome using a multi- organ-dysfunction score. Eur J Vasc Endovasc Surg 2000;19:190-6. 4. Eliason JL, Upchurch GR Jr. Endovascular abdominal aortic aneurysm repair. Circulation 2008;117:1738-44. 5. Sajid MS, Desai M, Haider Z, Baker DM, Hamilton G. Endovascular aortic aneurysm repair (EVAR) has significantly lower perioperative mortality in comparison to open repair: a systematic review. Asian J Surg 2008;31:119-23. 6. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 2011: Version 5.1.0. The Cochrane Collaboration. Available at: www.cochrane-handbook.org. Accessed March 2012. 7. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta- analyses. Ann Intern Med 2001;135:982-9. 8. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13. 9. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12. 10. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 2008;336:601-5. 11. Gluud C, Nikolova D, Klingenberg S, Alexakis N, Als-Nielsen B, D’Amico G, et al. Cochrane Hepato-Biliary Group. About the Cochrane Collaboration (Cochrane Review Groups [CRGs]). Chapter 8. Art. No. LIVER. 2008;4: Available at: http://www.mrw.interscience.wiley.com/ cochrane/cochrane_clsysrev_crglist_fs.html. Accessed November 6, 2009. 12. Duval S, Tweedie R. Trim and fill: a simple funnel-plot based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63. 13. Cuypers PW, Gardien M, Buth J, Peels CH, Charbon JA, Hop WC. Randomized study comparing cardiac response in endovascular and open abdominal aortic aneurysm repair. Brit J Surg 2001;88:1059-65. 14. EVAR Trial Participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR Trial 1): randomised controlled trial. Lancet 2005;365:2179-86. 15. Brown LC, Thompson SG, Greenhalgh RM, Powell JT. Incidence of cardiovascular events and death after open or endovascular repair of abdominal aortic aneurysm in the randomized EVAR trial 1. Brit J Surg 2011;98:935-42. 16. De Bruin JL, Baas AF, Buth J, Prinssen M, Verhoeven E, Cuypers P, et al. Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med 2010;362:1881-9. 17. Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT Jr, Matsumura JS, Kohler TR, et al; Open Versus Endovascular Repair (OVER) Veterans Affairs Cooperative Study Group. JAMA 2009;302: 1535-42. 18. Lifeline Registry of EVAR Publications Committee. Lifeline registry of endovascular aneurysm repair: long-term primary outcome measures. J Vasc Surg 2005;42:1-10. 19. Cao P, Verzini F, Parlani G, Romano L, De Rango P, Pagliuca V, et al. Clinical effect of abdominal aortic aneurysm endografting: 7-year concurrent comparison with open repair. J Vasc Surg 2004;40:841-8. 20. Sicard GA, Zwolak RM, Sidawy AN, White RA, Siami FS. Endovas- cular abdominal aortic aneurysm repair: long-term outcome measures in patients at high-risk for open surgery. J Vasc Surg 2006;44:229-36. 21. Moore WS, Matsumura JS, Makaroun MS, Katzen BT, Deaton DH, Decker M, et al. Five-year interim comparison of the Guidant bifur- cated endograft with open repair of abdominal aortic aneurysm. J Vasc Surg 2003;38:46-55. 22. Garcia-Madrid C, Josa M, Riambau V, Mestres CA, Muntana J, Mulet J. Endovascular versus open surgical repair of abdominal aortic aneurysm: a comparison of early and intermediate results in patients suitable for both techniques. Eur J Vasc Endovasc Surg 2004;28: 365-72. 23. Bush RL, Johnson ML, Hedayati N, Henderson WG, Lin PH, Lumsden AB. Performance of endovascular aortic aneurysm repair in high-risk patients: results from the Veterans Affairs National Surgical Quality Improvement Program. J Vasc Surg 2007;45:227-33; discus- sion: 233-5. 24. Hatala R, Keitz S, Wyer P, Guyatt G. Tips for learners of evidence- based medicine: 4. Assessing heterogeneity of primary studies in systematic reviews and whether to combine their results. CMAJ 2005;172:661-5. 25. Raffetto JD, Cheung Y, Fisher JB, Cantelmo NL, Watkins MT, Lamorte WW, et al. Incision and abdominal wall hernias in patients with aneurysm or occlusive aortic disease. J Vasc Surg 2003;37:1150-4. 26. Leurs LJ, Buth J, Laheiji RJ; EUROSTAR Collaborators. Long-term results of endovascular abdominal aortic aneurysm treatment with the first generation of commercially available stent grafts. Arch Surg 2007;142:33-41. 27. United Kingdom EVAR Trial Investigators. Endovascular repair of aortic aneurysm in patients physically ineligible for open repair. N Engl J Med 2010;362:1872-80. 28. Peterson BG, Matsumura JS, Brewster DC, Makaroun MS. Five-year report of a multicenter controlled clinical trial of open versus endo- vascular treatment of abdominal aortic aneurysms. J Vasc Surg 2007;45:885-90. Submitted Oct 25, 2012; accepted Feb 2, 2013. Additional material for this article may be found online at www.jvascsurg.org. JOURNAL OF VASCULAR SURGERY Volume 57, Number 6 Qadura et al 1683
  • 9. Study or Subgroup Bush23 Cao19 Garcia-Madrid22 Lifeline registry18 Moore21 Sicard20 Total (95% CI) Total events Heterogeneity: Tau² = 0.09; Chi² = 6.81, df = 5 (P = .24); I² = 27% Test for overall effect: Z = 2.19 (P = .03) M-H, Random, 95% CI 1.53 [1.00-2.35] 4.38 [1.68-11.40] 1.77 [0.26-11.91] 0.71 [0.26-1.96] 1.55 [0.43-5.54] 1.74 [0.52-5.79] 1.66 [1.05-2.62] oitaRksiRoitaRksiR M-H, Random, 95% CI Favors Open Favors EVAR 0.1 0.2 0.5 1 2 5 10 Supplementary Fig 1 (online only). Forest plot of prospective studies comparing 30-day mortality rate after endovascular aneurysm repair (EVAR) and open repair of unruptured abdominal aortic aneurysms (AAAs). Endo- vascular and open repair had similar 30-day postoperative all-cause mortality. CI, Confidence interval. Study or Subgroup Bush23 Cao19 Garcia-Madrid22 Lifeline registry18 Moore21 Peterson28 Sicard20 Total (95% CI) Total events Heterogeneity: Tau² = 0.19; Chi² = 34.15, df = 6 (P < .00001); I² = 82% Test for overall effect: Z = 1.66 (P = .10) M-H, Random, 95% CI 1.33 [1.03-1.71] 0.73 [0.56-0.95] 2.43 [0.58-10.09] 0.51 [0.38-0.70] 0.77 [0.47-1.26] 0.36 [0.19-0.67] 0.60 [0.36-1.01] 0.73 [0.50-1.06] oitaRksiRoitaRksiR M-H, Random, 95% CI Favors Control Favors EVAR 0.1 0.2 0.5 1 2 5 10 Supplementary Fig 2 (online only). Forest plot of prospective studies comparing long-term mortality rate after endovascular aneurysm repair (EVAR) and open repair of unruptured abdominal aortic aneurysms (AAAs). There was no statistical difference in long-term all-cause mortality between endovascular and open repair of AAAs. CI, Confidence interval. JOURNAL OF VASCULAR SURGERY 1683.e1 Qadura et al June 2013